Thrombopoietin mimetics vs placebo
Serious adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes onlyRR 0.89 [0.54, 1.46]4 studies · 356 participantsVery low